IMT Header

Cambridge Healthtech Institute’s Tenth Annual
Novel Vaccines
Part Two: Emerging Technologies
August 25-26


Vaccine technology has evolved significantly in the last decade, profoundly changing the future of vaccine development. The urgent need to accelerate response time to emerging threats, make vaccines more widely available and ready for quick deployment, develop vaccines against difficult targets, and improve delivery systems for maximum potency have been the impetus behind many advances in vaccine technology. Synthetic vaccine candidates, genomic analysis of disease progression and vaccine response, structure-based antigen design, and novel nanoparticle delivery systems are just a few of the realizations of this effort. CHI’s Tenth Annual Novel Vaccines: Emerging Technologies will present the latest advancements and applications of vaccine technology, and a look forward to overcoming current challenges. 


ADVANCES IN VACCINE TECHNOLOGIES

Keynote Presentation: Talk Title to be Announced

Nathalie Garcon, Ph.D., PharmD, CSO, Bioaster

Novel Delivery Technologies for Prophylactic Immunization

Manmohan Singh, Ph.D., Head, Translational Research, Drug Product and Analytical Development, Novartis Influenza Vaccines


DEVELOPMENT OF DNA VACCINES

Development of Potent Influenza DNA Vaccines that can Elicit Broad Cross-Protective Anti-Hemaggultination Responses against Diverse Viral Isolates Using SynCon® Technology

Jian Yan, Ph.D., Senior Scientist, Inovio Pharmaceuticals

A Step-Change in Epitope Design Enables a Pipeline of Multi-Antigen DNA Tumor Vaccines

William Watt, Ph.D., CEO & Co-Founder, EpiThany, Inc.; University of Washington Tumor Vaccine Group


VIRUS-LIKE PARTICLES AND NANOPARTICLES

Enveloped Virus-Like Particles – A Novel & Immunogenic Expression Platform

Adam Buckley, MBA, Vice President, Business Development, VBI Vaccines, Inc.

Tolerogenic Synthetic Nanoparticles for the Treatment of Autoimmune Diseases

Takashi K. Kishimoto, Ph.D., CSO, Selecta Biosciences


NGS IN VACCINE DISCOVERY AND DEVELOPMENT

Statistical Phylogenetic Analysis of Post-Immunization Clonal Dynamics

Thomas B. Kepler, Ph.D., Professor, Microbiology, Professor, Mathematics and Statistics, Boston University School of Medicine

Antibody Discovery and Vaccine Design – The Next Generation

Jiang Zhu, Ph.D., Investigator, Scripps Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID); Assistant Professor, Immunology & Microbial Science, and Integrative Structural & Computational Biology, The Scripps Research Institute


VACCINES FOR GLOBAL HEALTH

Ebola Virus Vaccine Development

Nancy Sullivan, Ph.D., Chief, Biodefense Research Section, Vaccine Research Center, NIH

Development of a Human Vaccine and Therapy Post Exposure Prophylaxis against Hendra and Nipah Viral Infections

Timothy Fouts, Ph.D., Senior Director, Virology, Profectus BioSciences

New Concepts in HIV Vaccine Development

Kathryn Stephenson, M.D., MPH, Instructor, Medicine, Center for Virology and Vaccine Research/BIDMC, Harvard Medical School

Elimination of the Cold-Chain Dependence of a Nanoemulsion Adjuvanted Vaccine against Tuberculosis by Lyophilization

Ryan M. Kramer, Ph.D., Scientist II, Characterization and Product Development Manager, Infectious Disease Research Institute


For more details on the conference, please contact:
Virginia Maxwell
Associate Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5436
E: vmaxwell@healthtech.com 

For exhibit & sponsorship opportunities, please contact:
Katelin Fitzgerald
Sr. Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5458
E: kfitzgerald@healthtech.com